Information Provided By:
Fly News Breaks for January 14, 2019
PRQR, BMRN
Jan 14, 2019 | 07:30 EDT
Cantor Fitzgerald analyst Eliana Merle found BioMarin's (BMRN) gene therapy platform advances and "improved risk-reward" for ProQR Therapeutics' (PRQR) USH2A program ahead of key data mid-2019 as most notable from the JPMorgan Healthcare Conference. The analyst left feeling more confident about BioMarin's gene therapy platform, which she thinks could positively surprise over the next 12-24 months as new programs enter the clinic. Further, she thinks the safety events in question at this point are likely overdone in ProQR shares following the 15% selloff since the conference. Merle now sees an "even more" favorable risk/reward into the company's mid-2019 proof-of-concept readout from a separate program.
News For BMRN;PRQR From the Last 2 Days
There are no results for your query BMRN;PRQR